Lack of Association Between Antiphospholipid Antibodies and Migraine

D A Tsakiris; L Kappos; G Reber; G A Marbet; J Le Floch-Rohr; E Roux; P de Moerloose

doi:10.1055/s-0038-1651625

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1993; 69(05): 415-417
DOI: 10.1055/s-0038-1651625

Original Article

Clinical Studies

Schattauer GmbH Stuttgart

Lack of Association Between Antiphospholipid Antibodies and Migraine

D A Tsakiris

¹The Coagulation and Fibrinolysis Laboratory, University Hospital of Basel, Switzerland

,

L Kappos

²Department of Neurology, University Hospital of Basel, Switzerland

,

G Reber

³Haemostasis Unit, University Cantonal Hospital, Geneva, Switzerland

,

G A Marbet

¹The Coagulation and Fibrinolysis Laboratory, University Hospital of Basel, Switzerland

,

J Le Floch-Rohr

⁴Department of Neurology, University Cantonal Hospital, Geneva, Switzerland

,

E Roux

⁵Division of Rheumatology, University Cantonal Hospital, Geneva, Switzerland

,

P de Moerloose

³Haemostasis Unit, University Cantonal Hospital, Geneva, Switzerland

› Author Affiliations

Abstract

PDF Download

Summary

We prospectively studied the prevalence of lupus anticoagulant, anticardiolipin antibodies (aCL) and various haemostatic parameters in 71 patients with migraine and compared the results with a control group of 32 subjects with back pain never having experienced migraine. The patients with migraine were divided into two groups: group I with migraine without (n = 18) and with aura lasting less than 60 min (n = 24) and group II with migraine with prolonged aura or migrainous infarction (complicated migraine, n = 29). The following results were obtained: a) no difference in aCL positivity was noted between migrainous patients and controls and between common migraine and complicated migraine patients and b) no statistically significant difference in haemostatic parameters (except for thrombin-antithrombin III complexes) was found between the two groups of migraine and between aCL positive and negative migrainous patients. These data suggest that anticardiolipin antibodies are not involved in the pathogenesis of migraine complications.

PDF (640 kb)

References

References
1 Harris EN. Antiphospholipid antibodies. Br J Haematol 1990; 74: 1-9
2 Galli M, Comfurius P, Maasen C. et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-1547
3 Mc Neil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid binding inhibitor of coagulation: β₂-Glycoprotein I (Apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4124
4 Tobelem G, Cariou R, Camez A. The lupus anticoagulant and its role in thrombosis. Blood Rev 1987; 1: 21-24
5 Freyssinet JM, Wiesel ML, Gauchy J, Boneu B, Cazenave JP. An IgM lupus anticoagulant that neutralizes the enhancing effect of phospholipid on purified endothelial thrombomodulin activity. A mechanism for thrombosis. Thromb Haemostas 1986; 55: 309-313
6 Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990; 76: 101-107
7 Tsakiris DA, Settas L, Makris PE, Marbet GA. Lupus anticoagulant -antiphospholipid antibodies and thrombophilia. Relation to protein C-protein S-Thrombomodulin. J Rheumatol 1990; 17: 785-789
8 Love PE, Santoro SA. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med 1990; 112: 682-698
9 Levine SR, Welch KMA. The spectrum of neurological disease associated with antiphospholipid antibodies. Arch Neurol 1987; 44: 876-883
10 Briley DP, Coull BM, Goodnight SH Jr. Neurological disease associated with antiphospholipid antibodies. Ann Neurol 1989; 25: 221-227
11 Markus HS, Hopkinson N. Migraine and headache in systemic lupus erythematosus and their relationship with antibodies against phospholipids. J Neurol 1992; 239: 39-42
12 Levine SR, Joseph R, D⁉Andrea G, Welch KM. Migraine and the lupus anticoagulant. Case reports and review of the literature. Cephalalgia 1987; 7: 93-99
13 Montalbán J, Cervera R, Font J. et al. Lack of association between anticardiolipin antibodies and migraine in systemic lupus erythematosus. Neurology 1992; 42: 681-682
14 Alarcon-Segovia D, Deleze M, Oria CV. et al. Antiphospholipid antibodies and the antiphospholipid syndrome in SLE. A prospective analysis of 500 consecutive patients. Medicine 1989; 68: 353-365
15 Shuaib A, Barklay L, Lee MA, Suchowersky O. Migraine and antiphospholipid antibodies. Headache 1989; 29: 42-45
16 Hogan MJ, Brunet DG, Ford DM, Lillicrap D. Lupus anticoagulant, antiphospholipid antibodies and migraine. Can J Neurol Sci 1988; 15: 420-425
17 Hering R, Couturier EGM, Steiner TJ, Asherson RA, Clifford-Rose F. Anticardiolipin antibodies in migraine. Cephalalgia 1991; 11: 19-21
18 Brey RL, Hart RG, Sherman DG, Tegeler CH. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology 1990; 40: 1190-1196
19 Montalbán J, Titus F, Ordi J, Barquinero J. Anticardiolipin antibodies and migraine-related strokes. Arch Neurol 1988; 45: 603 (Letter)
20 Coull BM, Goodnight SH. Antiphospholipid antibodies, prethrombotic states, and stroke. Stroke 1990; 21: 1370-1374
21 Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 (Suppl. 07) 1-96
22 Pelzer H, Schwartz A, Heimburger N. Determination of human thrombin antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemostas 1988; 59: 101-106
23 Pelzer H, Schwartz A, Stuber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemostas 1991; 65: 153-159
24 Triplett DA, Brandt J. Laboratory identification of the lupus anticoagulant. Br J Haematol 1989; 73: 139-142
25 Thiagarajan P, Pengo V, Shapiro SS. The use of dilute Russel viper venom time for the diagnosis of lupus anticoagulant. Blood 1986; 68: 869-874
26 Schleider MA, Nachman RL, Jaffe EA, Coleman M. A clinical study of the lupus anticoagulant. Blood 1976; 48: 499-509
27 Exner T, Rickard KA, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioural pattern. Br J Haematol 1978; 40: 143-151
28 Triplett DA, Brandt JT, Kaczor D, Schaeffer J. Laboratory diagnosis of lupus inhibitors: a comparison of tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol 1983; 79: 678-682
29 Reber G, Tremblet C, Bernard C, Mermillod B, de Moerloose P. Buffer’s influence on the detection and quantitation of anticardiolipin measured by ELISA. Thromb Res 1990; 57: 215-226
30 Blau JN. Migraine: theories of pathogenesis. Lancet 1992; 339: 1202-1207
31 Olesen J, Edvinsson L. Migraine: a research field for the basic neurosciences. TINS 1991; 14: 3-5
32 Henrich JB, Horwitz RI. A controlled study of ischemic stroke risk in migraine patients. J Clin Epidemiol 1989; 42: 773-780
33 de Moerloose P, Reber G, Vogel JJ. Anticardiolipin determination: Comparison of three ELISA assays. Clin Exp Rheumatol 1990; 8: 575-577